Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as trospium chloride inhalation powder (TrIP)
trospium chloride · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 400 mg TrIP | EXPERIMENTAL | - |
| 800 mg TrIP | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| trospium chloride inhalation powder (TrIP) | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male or female COPD patients between the ages of 40 and 80 years * Smoking history of at least 10 pack years * Not currently using (or able to wash out of) any long acting bronchodilators Exclusion Criteria: * Candidate on a waiting list for surgery while on study * Using lo...
Trospium chloride is being developed as an inhalation powder for chronic obstructive pulmonary disease, or COPD. The inhaled formulation, called trospium chloride inhalation powder (TrIP), is designed to deliver the drug directly to the lungs. It is investigational and has been studied in a Phase 1 trial in patients with COPD.
Trospium chloride targets the muscarinic acetylcholine receptors CHRM2 and CHRM3, where it acts as an antagonist. By blocking these receptors, it is intended to reduce cholinergic signaling in the airways, which is relevant to conditions such as COPD. This mechanism is the basis for its development as an inhaled therapy.
Trospium chloride inhalation powder (TrIP) is being developed by Alkermes plc, which trades on the Nasdaq under the ticker ALKS. The company is responsible for the clinical program evaluating this inhaled formulation in patients with chronic obstructive pulmonary disease.
Trospium chloride inhalation powder (TrIP) is in Phase 1 clinical development. It has completed one Phase 1 trial in patients with chronic obstructive pulmonary disease. It is an investigational product and has not been approved by the FDA for any indication.
Trospium chloride inhalation powder (TrIP) has been studied in a single completed Phase 1 trial, NCT00465959, titled "Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease." The trial enrolled 24 participants in the United States and was randomized, double-blind, and placebo-controlled.
Trospium chloride inhalation powder (TrIP) is an inhaled formulation of trospium chloride. The active drug is trospium chloride, a small molecule muscarinic antagonist, while TrIP refers specifically to the inhalation powder version developed by Alkermes for chronic obstructive pulmonary disease. They are not separate drugs but different formulations of the same active ingredient.